Mycophenolate Mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience.

TREATMENT FOR GVHD after allogeneic-related and -unrelated BMT is one of the most critical elements in the reduction of transplant-related morbidity and mortality. The high incidence of aGVHD indicates that more effective therapy and prevention of this severe complication is needed. MMF is a potent, uncompetitive, reversible inhibitor of eukaryotic inosine monophosphate dehydrogenase and is used successfully for the prevention of acute rejection in renal allograft recipients. Two years ago, we showed that MMF can be safely and effectively used for the treatment of aGVHD. In addition, MMF significantly decreased the use of prednisolone for the treatment of acute and chronic GVHD. Recently, we also demonstrated that MMF can be used safely for the prophylaxis of aGVHD in patients at high risk for aGVHD. The aim of our study was to report on our 4 years of experience using MMF in the treatment of acute and chronic GVHD.